Related Experiment Video

Updated: Mar 3, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

Outcome Measures for Clinical Trials in Down Syndrome

Anna J Esbensen¹, Stephen R Hooper¹, Deborah Fidler¹

¹Anna J. Esbensen, Cincinnati Children's Hospital Medical Center; Stephen R. Hooper, University of North Carolina - Chapel Hill; Deborah Fidler, Colorado State University; Sigan L. Hartley, University of Wisconsin - Madison; Jamie Edgin, University of Arizona; Xavier Liogier d'Ardhuy, Roche Innovation Center Basel; George Capone, Kennedy Krieger Institute; Frances A. Conners, University of Alabama; Carolyn B. Mervis, University of Louisville; Leonard Abbeduto, MIND Institute, University of California, Davis School of Medicine; Michael Rafii, University of Southern California and University of California, San Diego; Sharon J. Krinsky-McHale, New York State Institute for Basic Research in Developmental Disabilities and Columbia University Medical Center; Tiina Urv, Eunice Kennedy Shriver National Institute of Child Health and Human Development; and Outcome Measures Working Group. Note: Outcome Measures Working Group Participants: Cognition Working Group-Leonard Abbeduto, Frances Conners, Jamie Edgin, Michael Harpold, Stephen Hooper, Sharon J. Krinsky-McHale, Nancy Raitano Lee, Xavier Liogier d'Ardhuy, Carolyn Mervis, Roger Reeves, Michael Ropacki, Paul Wang; Behavior Working Group-George Capone, Elisabeth Dykens, Anna Esbensen, Deborah Fidler, Sigan Hartley, Seth Keller, Michael Rafii, Sara Weir.

American Journal on Intellectual and Developmental Disabilities

|April 29, 2017

Abstract:

Increasingly individuals with intellectual and developmental disabilities, including Down syndrome, are being targeted for clinical trials. However, a challenge exists in effectively evaluating the outcomes of these new pharmacological interventions. Few empirically evaluated, psychometrically sound outcome measures appropriate for use in clinical trials with individuals with Down syndrome have been identified. To address this challenge, the National Institutes of Health (NIH) assembled leading clinicians and scientists to review existing measures and identify those that currently are appropriate for trials; those that may be appropriate after expansion of age range addition of easier items, and/or downward extension of psychometric norms; and areas where new measures need to be developed. This article focuses on measures in the areas of cognition and behavior.

Keywords:

Down syndrome assessment behavior clinical trials cognition intellectual disability

More Related Videos

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

Published on: March 7, 2025

Measuring the Functional Abilities of Children Aged 3-6 Years Old with Observational Methods and Computer Tools

Measuring the Functional Abilities of Children Aged 3-6 Years Old with Observational Methods and Computer Tools

Published on: June 20, 2020

Related Concept Videos

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Karyotyping

Karyotyping

Articles linked to this work by shared authors, journal, and citation graph.

Tablet Assessment of Cognition in Down Syndrome: Comparison of Researcher and Caregiver Administration.

Journal of intellectual disability research : JIDR·2026

Expressive Language Sample Concordance With ADOS-2 Scores: Autism, Down Syndrome, Fragile X Syndrome.

American journal on intellectual and developmental disabilities·2026

Preliminary evaluation of an adapted snack delay task for measuring inhibition in young children with Down syndrome.

Research in developmental disabilities·2026

Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Blood biomarkers predict conversion from cognitively stable to mild cognitive impairment or Alzheimer's disease in Down syndrome at 16-month follow-up in ABC-DS.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.

Neuromolecular medicine·2026

See all related articles